+175.1%
MPC vs MRNA
+27.0%
+148.1%
-44.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.4% | -3.4% | +3.8% | +0.4% |
| 7D | +3.2% | -10.1% | +13.3% | +3.3% |
| 30D | +25.0% | +126.7% | -101.7% | +23.8% |
| 3M | +55.2% | +184.1% | -129.0% | +51.6% |
| 6M | +86.4% | +143.3% | -56.9% | +83.3% |
| YTD | +148.5% | +359.9% | -211.4% | +135.2% |
| 1Y | +121.7% | +454.2% | -332.5% | +106.7% |
| All | +175.1% | +27.0% | +148.1% | +145.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling